Xiaoxuan Tu

发表

Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?

P. Zhao, W. Fang, Wei Wu, 2019, World journal of clinical cases.

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Shunfeng Cai, N. Qin, P. Zhao, 2019, Journal of Immunotherapy for Cancer.

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin

P. Zhao, W. Fang, Weilin Wang, 2018, British Journal of Cancer.

Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy

W. Fang, Junwei Liu, Weiwei Yin, 2022, Journal for ImmunoTherapy of Cancer.

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin

P. Zhao, W. Fang, Weilin Wang, 2018, British Journal of Cancer.

Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy

P. Zhao, W. Fang, Shuwen Han, 2020, Supportive Care in Cancer.

Ultra-stable biomembrane force probe for accurately determining slow dissociation kinetics of PD-1 blockade antibodies on single living cells.

W. Fang, Bingfeng Ju, Wei Hu, 2020, Nano letters.

Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer

W. Fang, Xujun Zhang, Qingyi Cao, 2021, Cancer medicine.

The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient.

Z. Tong, Yi Zheng, Lulu Liu, 2024, Cancer gene therapy.

S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function

Z. Tong, Yi Zheng, Lulu Liu, 2024, Journal of experimental & clinical cancer research : CR.